Lunai Bioworks Inc. experienced a significant rally in extended trading on Tuesday, with shares soaring 80.88% to $5.15, following a company filing that revealed Nasdaq had confirmed compliance with the $1 minimum bid-price rule. This development removes the immediate threat of delisting, a key concern for the biotechnology firm. The stock was quoted at $4.65 early Wednesday, with reported volume of 13.48 million shares, far exceeding its average volume of 1.98 million.
The compliance notice, detailed in an 8-K filing signed by CEO David Weinstein and filed on June 16, comes after Lunai executed a 1-for-8 reverse stock split on May 22. Reverse splits are often used by companies to artificially boost share prices to meet exchange listing requirements. The split reduced outstanding shares from approximately 36.27 million to about 4.53 million. Nasdaq informed the company on June 11 that it had regained compliance.
Despite this positive news, the relief is not without caveats. Lunai remains under a one-year mandatory panel monitor imposed by Nasdaq, meaning any future failure to maintain the bid price above $1 could lead to immediate delisting without a grace period or compliance plan. Additionally, the company has flagged substantial doubt about its ability to continue as a going concern. As of March 31, Lunai reported only $3.16 million in cash, an accumulated deficit of $512.0 million, and a working capital deficit of $15.55 million, underscoring its urgent need for additional capital.
Lunai operates through its subsidiaries Renovaro Biosciences and BioSymetrics, focusing on AI-driven neurology and oncology diagnostics and therapeutic development. However, the company faces headwinds; GediCube, a unit acquired in 2024, filed for bankruptcy during the September 2025 quarter and has ceased operations. This places Lunai in a similar conversation as larger AI-linked drug-discovery firms like Recursion Pharmaceuticals and Schrödinger, though at a much smaller scale.
The broader market context remains muted. In after-hours trading on June 16, the S&P 500 was up 0.06%, the Nasdaq 100 rose 0.08%, the Dow Jones gained 0.09%, and the Russell 2000 was flat. Regular Nasdaq trading opens at 9:30 a.m. Eastern, with pre-market sessions from 4:00 a.m. U.S. equity markets are scheduled to close on Friday, June 19, for Juneteenth.
Lunai remains a thinly followed, highly volatile stock. Robinhood data places its market capitalization at $12.92 million, with a 52-week range of $1.21 to $31.04, highlighting the extreme price swings. For now, the market has rewarded the company for buying time on Nasdaq, but the next test will be whether Lunai can sustain its bid price above $1 and secure the funding needed to continue its drug-discovery and diagnostics operations.
